(Nasdaq: BDSX), a leading diagnostics solutions company, announced the publication of the largest lung nodule biomarker clinical validation study ever conducted. This milestone strengthens the ...

Safety and QoL considerations are reshaping sequencing, including avoidance of immunotherapy in certain drivers and adoption ...

The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management ...

Please provide your email address to receive an email when new articles are posted on . Acceptance and utilization of lung cancer biomarker testing has increased in the past 6 years, but key barriers ...

Amini: This varies quite a bit by stage — operable vs. nonoperable — and patients’ performance status and preference. Additionally, more relevant to medical oncology but equally, if not more, ...

Robert Kratzke, MD, urged insurance providers to prioritize fast biomarker testing in non–small cell lung cancer, saying it’s both cost-effective and life-saving. Delays in molecular testing for ...

Dr. Joshua K. Sabari sat down with Terri Conneran at the 2025 World Conference on Lung Cancer for a conversation on the importance of biomarker testing. Dr. Joshua K. Sabari, a thoracic medical ...

BOSTON — Key DNA and chromosomal and immune cell changes in early-stage lung adenocarcinoma show significant associations with outcomes, representing potentially important early predictors to guide ...

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, announced the publication of the largest lung nodule ...